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Increased visceral fat is associated with a high risk of
diabetes and metabolic syndrome and is in part
caused by excessive glucocorticoids (GCs). How-
ever, the molecular mechanisms remain undefined.
We now identify the GC-dependent gene LIM domain
only 3 (LMO3) as being selectively upregulated in a
depot-specific manner in human obese visceral adi-
pose tissue, localizing primarily in the adipocyte frac-
tion. Visceral LMO3 levels were tightly correlated
with expression of 11b-hydroxysteroid dehydroge-
nase type-1 (HSD11B1), the enzyme responsible for
local activation of GCs. In early human adipose stro-
mal cell differentiation, GCs induced LMO3 via the
GC receptor and a positive feedback mechanism
involving 11bHSD1. No such induction was observed
in murine adipogenesis. LMO3 overexpression pro-
moted, while silencing of LMO3 suppressed, adipo-
genesis via regulation of the proadipogenic PPARg
axis. These results establish LMO3 as a regulator of
human adipogenesis and could contribute a mecha-
nism resulting in visceral-fat accumulation in obesity
due to excess glucocorticoids.
INTRODUCTION
The study of human white fat-cell development and distribution
has become an important issue in the past decades due to the
immense prevalence of obesity and related disease. High risk
of developing metabolic disease is associated with amplified
visceral (VI) obesity, whereas obese subcutaneous (SC) adipose
tissue (SAT) presents a smaller or no risk andmay even beprotec-
tive (Gabriely et al., 2002; Jensen, 2008; Tran et al., 2008). These
differences in contribution to disease and function could be
caused by regional variations of replication and adipogenic
potential. Depot-specific fat mass expansion mechanisms may62 Cell Metabolism 18, 62–74, July 2, 2013 ª2013 The Authorsfacilitate drug development targeting particular fat depots. Fat-
depot differences in human adipogenic potential (SC > VI [Tchko-
nia et al., 2005; Tchkonia et al., 2013; Tchoukalova et al., 2010])
have been attributed to depot-specific intrinsic gene expression
signatures (Gesta et al., 2006; Macotela et al., 2012; Perrini
et al., 2013; Tchkonia et al., 2007) such as higher levels of PPARg
and C/EBPa in differentiating SC human adipose stromal cells
(hASCs) and their superior response to troglitazones (TZDs)
(Hauner et al., 1988; Tchkonia et al., 2002). Other modulators
could be extrinsic factors such as glucocorticoids (GCs), which
areknown topotentiatehumanadipogenesis (Morton, 2010;Tom-
linson et al., 2006; Wiper-Bergeron et al., 2007). Clinically, GCs
are widely used as immunosuppressants directly regulating
transcription via the glucocorticoid receptor (GR). The enzyme
11-b-hydroxysteroid dehydrogenase type 1 (11bHSD1) plays a
crucial role in determining intracellular (prereceptor level) GC
levels by regenerating active GCs (cortisol) from inactive metabo-
lites (cortisone) and is highly expressed in visceral adipose tissue
(VAT) (Bujalska et al., 2008; Morton, 2010; Walker and Andrew,
2006). In humans, the adipogenic-enhancing properties of GCs
are most obvious in the truncal obesity of Cushing’s syndrome
(Arnaldi et al., 2010), as well as in patients on systemic immuno-
suppressive corticosteroid treatment (McDonough et al., 2008).
In common for these individuals are hypertension,VATexpansion,
and insulin resistance (Bjo¨rntorp and Rosmond, 2000).
In this study, we investigated the role of GCs in human
adipocyte differentiation by analyzing the transcriptome of
GC-induced primary hASCs. This approach identified LMO3, a
member of the LIM-only proteins (LMOs), known to be involved
in cell-fate determination and neurogenesis (Dawid et al., 1998;
Zheng and Zhao, 2007), as a critical GC-responsive proadipo-
genic regulator. Further, LMO3 was among the earliest factors
induced in the course of human but not mouse white adipocyte
differentiation. We demonstrate that LMO3 exerts its activity at
the interface between GC action and peroxisome proliferator-
activated receptor g (PPARg). Importantly, LMO3 was upregu-
lated in VAT (as compared to SAT) in obese humans and tightly
correlated with 11b-hydroxysteroid dehydrogenase type-1
(HSD11B1) expression. These findings present LMO3 as a
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high expression levels in human VAT, and (3) critical for human
adipocyte differentiation. Thus, LMO3 could provide an attrac-
tive target to interfere with human adipocyte differentiation in a
therapeutically relevant manner.
RESULTS
LMO3 Is A Target and Amplifier of GC Action
in Human VAT
One of the genes emerging from our screen of the hASC tran-
scriptome in response to Dexamethasone (Dex; full target list
in Table S1, available online) that fulfilled our selection criteria,
(1) high adipocyte expression and (2) lack of known function in
adipogenesis, was the adaptor protein LMO3 (Figure 1A, verified
by quantitative PCR in Figure S1A). Several natural as well as
synthetic GR ligands, including Dex, hydrocortisone (HC), corti-
costerone (CC), prednisone (dehydrocortisone) (PRD), and the
fluorinated steroids clobetazol (CBTZ) and fluticazone (FLTZ),
all potently induced LMO3 messenger RNA (mRNA), an effect
that was blunted by the GR antagonist RU486, suggesting a
role of the GR for LMO3 induction (Figures 1B and S1B). We
further silenced the GR to confirm our results utilizing RU486.
Transfection of hASCs with a GR-specific small interfering RNA
(siRNA), or siGR, resulted in efficient silencing of GR mRNA
and protein (Figures 1C and 1D), in contrast to control
siRNA (siCtrl). Importantly, siCtrl-transfected hASCs displayed
a robust induction of LMO3 mRNA expression upon Dex treat-
ment, and no such induction was observed upon GR silencing
(Figure 1E). To further determine whether GCs upregulate
LMO3 via the GR, we performed transient transfection studies
with a luciferase reporter construct of the LMO3 promoter. GR
cotransfection resulted in an approximately 2.5-fold activation
of LMO3 promoter luciferase activity, further enhanced upon
treatment with GR ligand Dex. Importantly, LMO3 promoter
activity was blocked when 293FT cells were cotreated with
RU486 (Figure 1F). Of note, Dex failed to induce Lmo3 expres-
sion in murine adipose stromal cells (mASC) and 3T3-L1 preadi-
pocytes (Figure S1C).
The promoter regions of GR target genes typically contain one
or more GC response elements (GREs), defined by the canonical
sequence AGAACAnnnTGTTCT. Many variations of the
consensus sequence are possible, including GRE half sites,
which are sufficient to generate specific GR binding (van der
Laan and Meijer, 2008). Bioinformatic analysis of the proximal
promoter region of human LMO3 revealed two putative GRE
half sites, defined by the sequence 930TGTTTC924 (GRE1)
and 742AAAACA736 (GRE2) (Figure 1G). Deletion constructs
were created to identify which potential GR-binding sites were
involved in transactivation from the LMO3 promoter reporter
construct. Loss of both GRE1 and GRE2 resulted in diminished
transactivation, while constructs containing solely GRE2 or
both GREs showed potent transactivation (Figure 1G). Dex failed
to induce Lmo3 expression in mouse-derived adipocytes and
bioinformatic analysis revealed lack of GRE1 conservation in
the mouse Lmo3 promoter. Therefore, we verified the lack of
Lmo3 expression by exchanging the human with the noncon-
served murine GRE1 site (Figure 1G). Again, Dex significantly
increased luciferase reporter activity of the original human pro-moter plasmid (pLMO3-Luc-Hs.), an effect markedly blunted in
the luciferase reporter plasmid harboring the murine GRE1 site
(pLMO3-Luc-Hs.>Mm.; Figure 1H).
As endogenous GCs need to be activated by 11bHSD1, we
tested whether LMO3 induction is dependent on this mechanism
by blocking 11bHSD1 activity with the pharmacologic inhibitor
carbenoxolone. This not only prevented PRD-induced LMO3
expression, but also reduced differentiation into mature adipo-
cytes (Figures 1I and S1D). To elucidate whether LMO3 feeds
back into HSD11B1 expression levels, we silenced LMO3
in hASCs. Significantly reduced HSD11B1 expression was
observed (Figure 1J), suggesting a positive functional correlation
between LMO3 and 11bHSD1 activity, thus comprising partially
the permissive role of GCs for adipogenesis. To identify compo-
nents of the adipogenic cocktail able to induce LMO3 expres-
sion, we assessed the individual components during the early
stages of differentiation (24–48 hr). Among the individual compo-
nents, solely GR ligands Dex and HC, significantly induced
LMO3 in both hASCs and Simpson Golabi Behmel syndrome
(SGBS) cells, that are biochemically and functionally similar to
human adipocytes (Wabitsch et al., 2001) (Figures 1K and
S1E). Again, cotreatment with RU486 potently blocked LMO3
expression in hASCs (Figure 1K).
Interestingly, paired SAT and VAT samples of 55 obese study
participants (Todoric et al., 2011) (Table S2) revealed an
increased expression of LMO3 in VAT compared to SAT, a
finding in line with our observation that GCs induce LMO3 in
human fat cells (Figure 1L). To consider the possibility that mac-
rophages present in VAT of obese individuals could account for
increased VAT LMO3 expression, we measured the proportional
contribution fromdifferent cell types present in VAT. Analysis of a
previously published cohort of subfractionated VAT obtained by
cell sorting (Zeyda et al., 2007) confirmed the highest LMO3
mRNA expression in mature adipocytes compared with other
cell types including macrophages (Figure 1M). To account for
LMO3 expression arising from CD68-expressing adipose tissue
macrophages, we repeated our human paired SAT and VAT
comparison on a subset of obese nondiabetic study participants
that displayed adipose CD68 mRNA levels comparable to sam-
ples obtained from lean control subjects (Table S3). Importantly,
this approach further validated our finding obtained from the
entire study cohort and clearly showed that VAT displays sub-
stantial higher LMO3 levels than SAT (Figure S1F). Furthermore,
no correlation between LMO3 andCD68mRNA levels was found
in the ‘‘obese CD68LOW’’ subcohort (Figure S1G). In contrast to
cell culture models of adipocyte differentiation in which GCs
are added at the beginning of differentiation, white adipose
tissue (WAT) 11bHSD1 activity in vivo provides continuous
exposure of GCs. Thus, we investigated whether LMO3 and
HSD11B1 mRNA expression correlate in vivo in WAT and found
a strong positive correlation in VAT, but not SAT, in obese sub-
jects (Figure 1N), irrespective of CD68 expression (Figure S1H
and Table S3). To explore whether LMO3 functionally affects
VAT upon GC treatment, we performed gene expression
profiling on LMO3-silenced hASCs isolated from matched SAT
and VAT from several donors (Figures 1O and S1J–S1L and
Table S4). This analysis revealed (1) higher basal LMO3
levels in VAT- as compared with SAT-derived preadipocytes
(Figure S1I), (2) impaired HC-mediated gene induction inCell Metabolism 18, 62–74, July 2, 2013 ª2013 The Authors 63
(legend on next page)
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HC-responsive genes (Figure S1J), (3) importantly, no differ-
ences in SAT-derived hASCs upon silencing of LMO3 (Figure 1O
left versus right panel), and (4) LMO3-dependent and VAT-spe-
cific enrichment of genes regulating cell differentiation, commu-
nication, and adhesion, as well as signal transduction. Of note,
several of these LMO3-enriched genes are well known GC tar-
gets, such as inhibitor of growth family, member 2 (ING2),
TBC1 domain family, member 2B (TBC1D2B), tumor necrosis
factor (ligand) superfamily, member 10 (TNFSF10), C-X-C motif
chemokine 5 (CXCL5), and ecto nucleotide pyrophosphatase/
phosphodiesterase 2 (ENPP2) (Bujalska et al., 2006; Lu et al.,
2007; Viguerie et al., 2012) (Figures S1K and S1L). These data
suggest that the (ligand-bound) GR is critical for GC-mediated
LMO3 expression. Further, LMO3 is a specific target and
amplifier of GC action in human adipocytes displaying a VI fat
pattern, i.e., high levels of VI expression and close linkage with
HSD11B1 levels. Thus, LMO3 is modulating GC-triggered
responses of human (pre)adipocytes in a depot-, i.e., VAT-,
specific manner.
LMO3 Is Induced in Human Adipogenesis
In order to better understand the biological function of LMO3 in
adipose tissue/adipocytes, we examined whether LMO3 is regu-
lated during fat-cell formation in vivo and in vitro. DNAmicroarray
analysis of hASCs treated with an adipogenic cocktail revealed
strong induction of LMO3, whereas other LMO family members
were unaffected (Figure 2A). The LMO3 expression pattern
was determined in hASCs isolated from SAT, but also holds
true for VAT-derived hASCs and for SGBS preadipocytes,
when induced to differentiate into mature adipocytes (Figures
2B and S2A). Furthermore, mature adipocyte markers ADIPOQ,
LPL, PLIN,CD36, and FABP4 and the transcriptional master reg-
ulators PPARG and CEBPA confirmed successful generation of
mature adipocytes (Figures 2B, S2A, and S2B). Adipose tissue
LMO3 mRNA expression was among the top 25% of all human
tissues examined (Figure 2C). Importantly, LMO3 protein levels
could be detected simultaneously with the master regulators
PPARg andCEBPa in hASCs induced to differentiate intomature
adipocytes (Figure 2D). Fractionation of WAT allowed us to iden-
tify mature adipocytes as the dominant site of LMO3mRNA andFigure 1. LMO3 Expression Is Regulated by the GC Receptor
(A) hASCs were treated with Dex and mRNA isolated on indicated time points. F
(B) LMO3 expression 24 hr after addition of GCs to hASCs in growth medium ±R
(C and D) mRNA (C) and protein (D) of GR in transfected hASCs treated for 24 h
(E) LMO3 mRNA in transfected hASCs with Dex treatment for 0 and 24 hr.
(F–H) LMO3 promoter analysis. 293FT cells were cotransfected with pcDNA and
promoter luciferase reporter plasmid (‘‘LUC’’; promoter construct shown above) (F
GRE1 site (pLMO3-Luc-Hs.>Mm.) (H). Twenty-four hours after transfection, cells
point mutations representing the murine sequence. Deletion constructs are show
(I) LMO3 mRNA expression in hASCs treated for 24 hr with vehicle, carbenoxolo
(J) HSD11B1 mRNA during the indicated days of differentiation in transfected hA
(K) LMO3 mRNA in hASCs after adding individual components of the adipogenic
(L) Depot-specific expression of LMO3 mRNA in paired obese human SAT and V
(M) Human LMO3 mRNA expression in human VAT fractions normalized to Ubiq
(N) Linear regression analysis between LMO3 and HSD11B1 mRNA expression in
(O) RNA profiling of transfected hASCs derived from matched human SAT and VA
normalized mean fluorescence pooled from n = 3 for each treatment group. A su
All error bars represent means ± SEM. p values: ns, not significant; *p < 0.05, **p <
Table S4, Table S5, and Table S6.protein expression within WAT (Figures 2E and 2F). Thus, we
show in patient fat biopsies and in two well-established in vitro
models that LMO3 expression increases throughout adipogene-
sis. To determine subcellular LMO3 protein expression during
adipogenesis, we isolated cytoplasmic and nuclear protein
extracts throughout differentiation of hASCs into mature adipo-
cytes. We demonstrate a strong increase in LMO3 expression
from day 3 to day 7 that was detectable in cytoplasmic but not
nuclear fractions (Figure 2G). Restriction of LMO3 expression
to the cytoplasm was further corroborated by confocal immuno-
fluorescence analysis of hASCs undergoing differentiation (Fig-
ures 2H and S2C) showing no LMO3 signal in preadipocytes
(day 0) but strong cytoplasmic expression in perilipin (PLIN)-
positive adipocytes (day 6). Occasionally, WAT-resident CD68-
positive macrophages also stained positive for LMO3 (Figure 2I
and S2D). Perhaps most intriguing, LMO3 induction was specific
for human adipogenesis, asmurine adipocyte differentiation was
not accompanied by enhanced Lmo3 expression. Lack of Lmo3
expression was confirmed in (1) WAT of a mouse tissue library
(Figure S2E), (2) the murine 3T3-L1 adipocyte cell model
throughout differentiation (Figures 2J and S2F), and (3) differen-
tiating murine primary preadipocytes (Figure 2K), as well as in (4)
ASCs and mature adipocytes isolated from chow-fed or high-fat
diet (HFD)-challenged mice (Figures 2L and S2G), (5) distinct SC
and VI WAT depots and BAT of mice fed a low-fat diet (LFD) or
HFD (Figures 2M and S2H), and (6) WAT obtained from a genetic
obesity mouse model (db/db) on both LFD and HFD (Figures 2N
and S2I). Lmo3 expression was highest in the brain and therefore
was used as a positive control throughout analysis with murine
samples (Figures 2J–2N and S2G–S2I). Thus, LMO3 is a marker
of human adipogenesis not applicable for mice.
LMO3 Promotes Adipogenesis
To clarify the role of endogenous LMO3 in adipocyte differentia-
tion, we silenced the expression of LMO3 in subconfluent hASCs
using siRNA and induced differentiation. To reduce the risk of
potential off-target effects, we applied two different siRNA oligo-
nucleotides (referred to as siLMO3 #1 and siLMO3 #2) targeting
different LMO3 exons. Figures 3A and 3B show efficient LMO3
mRNA and protein knockdown in hASCs. Cells with reduced
LMO3 demonstrated diminished adipogenic potential, includingold change is compared to day 0 of Dex treatment.
U486. LMO3 in the absence of RU486 in growth medium was set to 1 (n = 3).
r with Dex.
/or GC receptor expression plasmid (pGR), as well as human full-length LMO3
), various deletion constructs (G, right), or LMO3 construct featuring the murine
were treated with DMSO, Dex, or RU486. Underlined letters, GRE half sites; *,
n below homology plot (G, left).
ne, or PRD in growth medium.
SCs.
cocktail or full mix (FM) in growth medium for 24 hr. (n = 3).
AT biopsies (n = 55). Horizontal bars indicate the mean.
uitin-C mRNA (n = 4).
obese human VAT. p values were obtained from regression analysis (n = 45).
T treated with DMSO or HC for 24 hr. Genes are represented as lines and are
mmary is shown in Table S4.
0.001, and ***p < 0.0001. See also Figure S1 and Table S1, Table S2, Table S3,
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Figure 2. Human, Not Mouse, LMO3 Is Induced during Adipocyte Differentiation
(A) LMO1-4 mRNA expression based on DNA microarray expression profiling. Fold change compared to day 0 of differentiation is shown.
(B) mRNA was determined in differentiating hASCs isolated from SAT or VAT as the mean fold change ± SEM (n = 3).
(C) LMO3 mRNA tissue distribution in humans. Each tissue is pooled from three donors.
(legend continued on next page)
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expression of adipocyte marker genes, including FABP4,
PLIN1, and LPL (Figures 3B [perilipin blot] and 3E). Importantly,
neither cell viability nor cell proliferation varied between siCtrl-
and siLMO3-treated hASCs under the experimental conditions
for adipocyte differentiation (Figures S3A and B). We additionally
verified the hASC requirement of GCs to potentiate the adipo-
genic program by excluding GCs. This resulted in almost com-
plete lack of mature adipocyte formation also in LMO3-silenced
hASCs, as expected (Figure S3C), demonstrating that GCs are
indeed necessary to induce adipogenesis in human preadipo-
cytes. To study the role of LMO3 in regulation of adipogenesis
in vivo, we subdermally administered control- or LMO3-silenced
hASCs into severe combined immunodeficient (SCID) mice. The
transplants were collected and histologically examined after
6 weeks. We confirmed the human origin of the collected cells
by immunofluorescent stainingwithMAB1281, a human-specific
nuclear antibody that does not stain mouse nuclei (Figures 3F
and S3D). Mature adipocytes also stained positive for the adipo-
cyte marker perilipin. We observed a significantly higher propor-
tion of hASC-derived mature adipocytes in tissues collected
from animals that were transplanted with siCtrl-treated hASCs
as compared to mice transplanted with siLMO3-transfected
hASCs (Figure 3G), underlining strong proadipogenic effects of
LMO3 also in vivo.
Next, we employed LMO3 gain-of-function studies to mini-
mize the risk that the siLMO3-triggered reduction of adipocyte
differentiation is an unspecific side effect due to our experi-
mental manipulations interfering with a highly coordinated, and
thus sensitive, cellular program. LMO3mRNA and protein levels
were significantly increased in LMO3 cells transfected with a
LMO3 expression plasmid relative to cells transfected with a
control plasmid (Figures 3H and 3I, pCtrl versus pLMO3-V5). In
accordance with our loss-of-function data elucidating LMO3 as
a proadipogenic mediator, overexpression of LMO3 in these
cells significantly enhanced adipogenesis, shown by increased
oil red O staining of neutral lipids (Figures 3J and 3K) and signif-
icant overexpression of the adipocyte markers FABP4, LPL, and
PLIN1 (Figure 3L). As LMO3 overexpression promotes adipo-
genesis and expression of genes facilitating lipid accumulation
in hASCs, we investigated whether visceral LMO3 expression
is linked to body mass index (BMI), waist circumference, or
HOMA-IR in our nondiabetic lean and obese patient cohorts
(Tables S5 and S6). Interestingly, and despite the fact that
HSD11B1 levels were robustly increased in the VAT of obese
study subjects displaying high HOMA-IR (Table S5), no such dif-
ference could be found for LMO3 expression.
Of note, siRNA mediated knockdown of mouse Lmo3 failed
to interfere with adipogenesis in 3T3-L1 cells (Figures S3E(D) Protein expression throughout differentiation in SAT-isolated hASCs.
(E and F) mRNA and (F) protein (F) expression in human SAT cell fractions (n = 9
(G) Protein expression in nuclear and cytosolic fractions in differentiating SAT-de
(H and I) Images are representative of multiple donors. Scale bars represent 20 mm
(I) are shown.
(J–N) Determination of protein expression in differentiating murine 3T3-L1s (J),
gonadal pads (n = 5) (K and I), the indicated cell subpopulations from C57Bl/6 p
perigonadal pads from db/db mice and littermate controls (db/+) (n = 3–4) (N).
All error bars represent the means ± SEM. p values: ns, not significant; **p < 0.0and S3F). Interestingly, when Lmo3 was overexpressed, it
exerted the phenotype observed in hASCs, i.e., enhanced adipo-
genesis (Figures S3G and S3H), implying that murine cells can
utilize Lmo3, but that due to lack of conservation in the GRE1
site, it is not inducible. Thus, LMO3 is a prerequisite to unveil
the full adipogenic potential of human preadipocytes.
LMO3 Boosts a Proadipogenic PPARg Program
We next sought to investigate the mechanism by which LMO3
promotes adipogenesis. Thus, we profiled genome-wide
expression changes that occur in response to the adipogenic
cocktail, comparing patterns between siCtrl- or siLMO3-treated
human preadipocytes on day 6 of differentiation, integrating both
primary and secondary effects of LMO3. Figure 4A shows 1,892
genes from adipogenesis-induced preadipocytes that displayed
at least a 1.5-fold expression change relative to day 0 and were
therefore selected as adipogenesis-induced genes. Approxi-
mately 4.6% of the adipogenic gene signature was affected by
LMO3 knockdownwith two independent siRNA oligonucleotides
targeting LMO3mRNA (Figure 4B). Hierarchical clustering parti-
tioned the 1,892-adipogenesis-induced genes into LMO3-inde-
pendent clusters 1 and 2 or LMO3-dependent clusters 3 and 4
(Figure 4C and Table S7). Pathway enrichment analysis of
LMO3-dependent cluster 3 revealed a highly significant enrich-
ment for PPAR signaling (Figure 4D). In agreement with the
pathway enrichment results, inspection of cluster 3 showed
that silencing of LMO3 (siLMO3) diminished expression levels
of several known PPARg target genes in hASCs (Figure 4E).
Therefore, we tested whether LMO3 modulates PPARg expres-
sion and/or activity. Western blotting of siCtrl- and siLMO3-
treated hASCs suggested a slight but nonsignificant impact on
PPARg protein expression (Figure 4F). We further investigated
whether PPARg activity is needed for the proadipogenic effects
of endogenous LMO3 on lipid accumulation. We silenced
PPARG (siPPARg) in hASCs overexpressing LMO3 (pLMO3-V5)
and evaluated lipid accumulation by oil red O staining in differen-
tiating hASCs 8 days later (Figures 4G–4I). As shown above
(Figures 3J and 3K), overexpression of LMO3 increased lipid
accumulation (Figures 4H and 4I, left panels). Of note, silencing
of the adipogenic master regulator PPARG (siPPARg) abolished
the proadipogenic effect of LMO3, suggesting that LMO3 acts
upstream of PPARg (Figures 4H and 4I, right panels). We next
determined whether LMO3 is able to modulate the transcrip-
tional activity of PPARg. We performed transfection assays in
293FT or 3T3-L1 cells with a reporter driven by isolated PPAR
response elements (PPREs). As expected, cotransfected
PPARG resulted in an increase in luciferase activity, in part
because of the ligand-independent activation function in its
amino terminus. Troglitazone (TZD) treatment further enhanced).
rived hASCs.
. Stainings in differentiating SAT-derived hASCs (H) and human VAT sections
primary murine adipose stromal cells (mASCs) isolated from C57BL/6J peri-
erigonadal pads (n = 5) (L), WAT depots from C57BL/6J mice (n = 5) (M), and
01 and ***p < 0.0001. See also Figure S2.
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Figure 3. RNA-Interference-Mediated Knockdown of LMO3 Suppresses, whereas Overexpression of LMO3 Promotes, Adipogenesis
(A, D, E, and G) Comparisons of control (siCtrl)- versus LMO3-silenced (siLMO3)-transfected cells.
(A and B) mRNA (A) and protein (B) verification of LMO3 silencing on the indicated days (blots day 6) of differentiation in transfected hASCs.
(C) Mature adipocytes (differentiation day 10) stained with oil red O. Microscopic views, magnifications 103.
(D) Quantification of oil red O staining in (C) (n = 3).
(E) RT-PCR analysis in transfected hASCs. (n = 3).
(F) Representative immunofluorescent staining of xenotransplanted SCIDmice. From left to right: top, bright-fieldmorphology of the transplant sections (the scale
bar represents 50 mm), zoomed bright-field image (the scale bar represents 20 mm), and immunofluorescent merge; bottom, DAPI (blue), MAB1281 (gray with
arrows), and perilipin (red) (immunofluorescent panels, the scale bar represents 20 mM).
(legend continued on next page)
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with increasing amounts of LMO3 expression plasmid increased
PPARG activity, which was further enhanced in the presence of
TZD (Figure 4J). Thus, LMO3 drives adipogenesis through
increasing PPARg tone.
A critical step required during adipogenesis is the downregu-
lation of mitogen-activated protein kinase extracellular signal-
regulated kinases (MAPK-ERKs) mediated phosphorylation at
serine 112 (S112) in the N-terminal region of PPARg, which
blocks PPARg to activate the full proadipogenic gene program
(Adams et al., 1997; Camp and Tafuri, 1997; Hu et al., 1996;
Shao et al., 1998). Interestingly, we found that loss of LMO3
resulted in increased serum-induced ERK1/2 phosphorylation
(p-p44/42 MAPK; Figure 4K), further supporting the observation
that LMO3 acts upstream of PPARg. To test whether LMO3
could directly inhibit ERK-dependent signaling, we performed
transient transfection assays using reporter plasmids that read
out ERK-dependent activation of the transcription factor ELK1.
Cotransfection of a LMO3 expression vector diminished the abil-
ity of EGF to activate the ELK1 reporter (Figure 4L). Importantly,
compared with control cells, the LMO3 knockdown cells not only
showed increased ERK1/2 phosphorylation but also 1.7-fold
increased phosphorylation levels of endogenous PPARg at
S112 (Figure S3I). Next, we addressed whether p-S112 is
involved in LMO3-mediated effects by making use of a mutant
PPARg-S112A, which renders PPARg refractory to p-S112-
mediated inactivation (Camp and Tafuri, 1997; Hu et al., 1996;
Shao et al., 1998). We initially tested whether LMO3 increases
TZD-mediated PPARg activity via S112 when a reporter driven
by isolated PPREs (AOx-TK) was used. As reported, mutant
PPARg-S112A displayed increased PPARg activity (Adams
et al., 1997). Again, LMO3 cotransfection boosted PPARg pro-
moter activity. However, and in sharp contrast, LMO3 was
unable to further increase the transcriptional activity of mutated
PPARg-S112A (Figure 4M). Similarly, cotransfection with an acti-
vated allele of MEK, the upstream kinase of ERK1/2, prevented
the stimulating effect of LMO3 on PPARg activity (Figure 4M).
In line with our previous results, LMO3 knockdown reduced adi-
pogenesis and the expression of PPARg target genes in hASCs
expressing wild-type PPARg (Figures 4N). However, and impor-
tantly, these LMO3-dependent effects were lost in hASCs trans-
fected with the mutated form of S112 PPARg (PPARg-S112A) or
the presence of a constitutively active MEK (Figure 4N). Thus,
interference with MAPK-ERK phosphorylation of PPARg is one
possiblemechanism bywhich LMO3 regulates human adipocyte
differentiation.
DISCUSSION
Obesity is associated with many metabolic consequences,
where VI fat accumulation produces a greater risk of diabetes,(G) Quantification of xenotransplanted SCID mice stainings.
(H, K, and L) Comparisons of control (pCtrl)- or LMO3 (pLMO3-V5)-transfected c
(H and I) mRNA (H) and protein (I) verification of LMO3 overexpressing transfecte
(J) Oil red O stain of overexpressing hASCs (differentiation day 10). Shown are m
(K) Quantification of oil red O stain in (J) (n = 3).
(L) RT-PCR analysis in pCtrl or pLMO3-V5 transfected hASCs. (n = 3).
All error bars represent the means ± SEM. p values: ns, not significant; *p < 0.05dyslipidemia, and accelerated atherosclerosis (Kissebah et al.,
1982; Wajchenberg, 2000). In this study, we aimed to identify
GC target genes involved in the differentiation of human
adipocytes, on the basis of (1) a hitherto unknown function
in adipocyte biology, (2) a robust induction in human adipo-
cyte differentiation models, and (3) the potential to act
upstream of the adipogenic master regulator PPARg. Using
these criteria, we identified among the top-most regulated
genes LMO3.
LMO3 promoter studies, GR silencing, GR antagonist RU486,
and several natural and synthetic GCs showed that LMO3 is a
direct GR target gene. Interestingly, we found that LMO3 is not
only induced by GCs and HSD11B1, but is also part of a positive
feedback loop enhancing GC action on adipocytes, a finding
paralleled by our data showing tightly correlated LMO3 and
HSD11B1 levels in human VAT but not SAT. Overexpression of
LMO3 in hASCs enhanced adipogenesis and was reflected by
enhanced adipogenic gene expression and enhanced lipid
accumulation. Knockdown of LMO3 in hASCs suppressed fat
differentiation both in vitro and in vivo. This collectively renders
LMO3 as an essential factor linking extrinsic factors (GCs)
with specific molecular mediators, resulting in progressed adi-
pogenesis. To better understand the role of LMO3 in human
depot-specific responses to GCs, we silenced LMO3 expression
in hASCs from matched SAT and VAT. Upon GC treatment, an
LMO3-dependent gene expression signature was observed
solely in VAT- but not SAT-derived preadipocytes, a finding
that may be related—at least in part—to the higher basal
LMO3 and HSD11B1 expression in VAT-derived preadipocytes.
Of note, both fat depots are responsive to the actions of LMO3
in vitro; however, in vivo measurements and SAT/VAT compari-
sons revealed a clear preference of VI preadipocytes for LMO3-
dependent GC action. Some of the LMO3-dependent genes
expressed in VI but not SC preadipocytes were ENPP2,
TNFSF10 or TBC1 domain family member 2B (TBC1D2B) poten-
tially having direct influence on (VI) fat-cell growth ormetabolism.
The lysophospholipase ENPP2 and its product, lysophosphati-
dic acid, have established effects on preadipocyte proliferation
and fat-tissue expansion, and its expression is enhanced in a
depot-specific manner in obese/insulin-resistant individuals
(Rancoule et al., 2012), whereas the secreted protein TNFSF10
regulates adipocyte metabolism through cleavage of PPARg
(Keuper et al., 2013). The GC-induced signaling nexus TBC1D2B
may enhance insulin signaling in a manner reported for its close
paralogues, TBC1D1, TBC1D3, and TBC1D4 (Pehmøller et al.,
2012; Wainszelbaum et al., 2012) in a LMO3-dependent manner
in VAT-, but not SAT-, derived preadipocytes, adding to adipose
depot-specific actions of insulin (Hazlehurst et al., 2013). We
now add LMO3 to the growing list of developmental regulators
controlling (depot-specific) adipocyte differentiation (Macotela
et al., 2012).ells.
d hASCs on the indicated days.
icroscopic views, magnifications 103 (n = 3).
, **p < 0.001, and ***p < 0.0001. See also Figure S3.
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Figure 4. LMO3 Promotes Adipogenesis via Increasing PPARg Tone
(A) Flow chart with experimental DNA microarray setup and gene selection process.
(B) Schematic pie chart of LMO3-dependent and -independent genes.
(C) Clusters of genes from the microarray screen. Red is up- and blue is downregulated genes.
(D) Pathway enrichment analysis shown as a Z score on LMO3-dependent genes (87 in total) with DAVID and EASE.
(E) Heatmap diagram of PPARg target genes within the LMO3-dependent gene signature. Experiments were performed in duplicates. *, independent validation
shown in Figure 3E. See Table S7 for LMO3-dependent target genes at day 6 of differentiation.
(legend continued on next page)
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Cell Metabolism
Human Adipogenesis Is Critically Dependent on LMO3Several observations led us to suggest that LMO3 enhances
adipogenesis via PPARg: (1) the most significant category
of genes suppressed after LMO3 silencing in differentiating
hASCswas PPARg target genes, (2) RNA-interference-mediated
silencing of PPARG during hASC differentiation abrogated
LMO3-enhanced lipid accumulation, and, most importantly, (3)
LMO3 overexpression enhanced PPARg transcriptional activity
in two cell models. These observations raised the question of
how cytoplasmic LMO3 enhances primarily nuclear PPARg
activity. One potential mechanism is the well studied inhibition
of PPARg activity by ERK1/2-mediated phosphorylation of
PPARg at serine 112 (Adams et al., 1997; Hu et al., 1996; Shao
et al., 1998). Interestingly, we observed that LMO3-deficient
cells displayed an increase in the amount of p-S112 PPARg
and p-ERK1/2, while LMO3-overexpressing cells display
reduced ERK1/2 pathway activity. Importantly, we were also
able to reverse the LMO3 knockdown-based phenotype by
PPARg -S112A transfection, a mutation that has been described
to render PPARg insensitive to pS112-inhibition (Adams et al.,
1997; Hu et al., 1996). Taken together, this supports our hypoth-
esis that LMO3 targeting of PPARg at serine 112 (via ERK1/2)
represents a major determinant altering adipocyte gene expres-
sion. Interestingly, a similar mechanism, i.e., lack of catalytic
activity and negative modulation of ERK1/2, has been reported
to underlie the proadipogenic effects of the cytoplasmic down-
stream of tyrosine kinase-1 (DOK1) (Hosooka et al., 2008).
Indeed, the LIM domains of LMO3 lack intrinsic catalytic (i.e.,
phosphatase) activity. However, as for DOK1, LIM proteins
mediate many biological processes acting as a docking site for
the assembly of multiprotein complexes (Kadrmas and Beckerle,
2004; Zheng and Zhao, 2007). Among others, potential LMO3
interaction partners include ERK activators MAPK kinases
(MAPKK/MEK) (Burgermeister et al., 2007), ERK1/2 themselves,
(Adams et al., 1997; Hu et al., 1996), phosphatases (Hinds et al.,
2011), and the signaling adaptor DOK1 (Hosooka et al., 2008).
The 11bHSD1/LMO3/ PPARg module provides differentiating
human (pre)adipocytes with a molecular switch, enabling the
cells to fine-tune their response to circulating GCs. 11bHSD1 is
expressed at high levels in VI fat depots (Bujalska et al., 1997,
2008; Morton, 2010; Walker and Andrew, 2006), and LMO3 is
also found at higher levels in VAT as compared to SAT. There-
fore, it is proposed that GCs drive human LMO3 expression
and thus its proadipogenic activities in a depot-specific, VI
manner. In such a scenario, low 11bHSD1 activities or its inhibi-
tion by pharmacologic targeting will result in (1) reduced VI LMO3(F) PPARg protein expression on day 6 of differentiation in transfected hASCs. D
(G) Silenced PPARG mRNA verification in transfected hASCs at day 9 of differen
(H) Oil red O staining of cells treated as in (G), magnifications 103.
(I) Quantification of (H). pCtrl/siCtrl-transfected cells are set to 1 for comparison.
(J) LMO3 enhances PPARg activation of a luciferase reporter driven by minimal P
(bottom) cells stimulated for 24 hr with DMSO or TZD. pcDNA with DMSO, set to
(K) Transfected and day 6 differentiated hASCs were serum starved overnight fol
blots. The bottom panels show densitometric evaluation.
(L) Luciferase reporter activity analysis of GAL-ELK-1 constructs in 293FT cells.
(M) 293FT cells transfected with wild-type (WT) PPARg or S112A mutant were an
presence or absence of LMO3 (n = 3).
(N) mRNA of mature adipocyte markers in hASCs with WT PPARg transfected
cotransfected with mutated PPARg S112A plasmid (gray bars). RNA was isolate
All error bars represent the means ± SEM. p values: ns, not significant; *p < 0.05levels, (2) reduced PPARg transcriptional activities, and, conse-
quently (3) reduced adipogenesis, specifically in VI fat.
An appealing question is why LMO3 can be averted in mouse
adipocytes andwhy there is no obvious functional consequence.
This is especially interesting, since ectopically expressed Lmo3
in murine 3T3-L1 cells enabled replication of the phenotype
observed in differentiated hASCs (i.e., enhanced adipogenesis).
As a direct consequence, Lmo3-dependent fine-tuning in mice
does not apply, not because mice cannot utilize Lmo3 to
enhance adipogenesis, but because the critical GC induction
site GRE1 is mutated in the mouse genome. Thus, LMO3 might
represent a mechanism by which—in contrast to mice—humans
can adapt and modulate the activity of the key adipogenic mas-
ter regulator PPARg. Although the basic molecular mechanisms
of fat-cell development are identical in rodents and humans—as
is the intact response of murine cells to reintroduced Lmo3—
many of the observed species-specific attributes likely stem
from when (and where) the products of the genes are made (Wil-
son et al., 2008) so that the timing of preadipocyte recruitment
and adipocyte differentiation is accessible to more subtle fine-
tuning mechanisms.
Interestingly, as opposed to HSD11B1, no correlations were
observed between LMO3 and BMI or HOMA-IR in our study
participants. However, the missing link of LMO3 expression
with our metabolic parameters needs to be interpreted with
caution since several circumstances may have blurred a poten-
tial relationship (specifically, considering observed HSD11B1
correlations with LMO3 in VAT of obese subjects; Table S6).
Among others, we cannot exclude the possibility that nonfat
cells in VAT may obscure the association of LMO3 with meta-
bolic parameters. Also, we cannot exclude that we missed the
best time point to collect our fat biopsies, i.e., it might have
been too late in the course of fat-cell recruitment and expan-
sion, especially in our obese study cohort. Further, GC circadian
rhythms may have masked pre-existing differences in LMO3
expression (Peckett et al., 2011). Further studies with highly
standardized measurements of circadian systemic and adipose
GC levels are needed to relate LMO3 with states of obesity and
diabetes.
Our current study (summarized in Figure 5) added LMO3 as a
proadipogenic protein and suggests that LMO3 modulates
human adipocyte differentiation by acting on PPARg, between
the early and late phase of adipocyte differentiation (Farmer,
2006). Our data also help to explain, at least in part, the long-
known but ill-defined effect of GCs on VAT. Finally, we proposeensitometric evaluation is shown below. (n = 3.)
tiation.
PAR-responsive elements (3X-PPRE) (‘‘pAOx-TK’’) in 293FT (top) and 3T3-L1
1 for comparison. (n = 3.)
lowed by 1 hr 40% fetal bovine serum (FBS). The top panels are representative
The construct is depicted above.
alyzed for TZD-induced reporter activity using PPRE-luciferase (as in J) in the
with either siCtrl or siLMO3 oligo (white and black bars) and/or additionally
d from cells on day 8 of differentiation.
, **p < 0.001, and ***p < 0.0001. See also Figure S3 and Table S7.
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Figure 5. LMO3 Is a Human Driver of Adipogenesis
Schematic model of the pathways controlling differentiation in hASCs.
Cell Metabolism
Human Adipogenesis Is Critically Dependent on LMO3that the preferential expression in VAT, the GC responsiveness,
and the functional location upstream of PPARg make LMO3 an
attractive target to interfere with human adipocyte differentiation
in a depot-specific, therapeutically relevant manner.
EXPERIMENTAL PROCEDURES
Human Samples and Clinical Parameters
Study subjects included 55 obese patients and seven nonobese controls
that underwent weight-reducing surgery or elective surgical procedures
such as cholecystectomy. Participants were included if they had fasting
plasma glucose levels <7.0 mmol/liter, no history of diabetes or use of
blood-glucose-lowering medications, no weight changes >3% during the
previous 2 months, and C-reactive protein (CRP) levels <20 mg/liter. All
study subjects provided informed consent, and study protocols were
approved by the local Ethics Committee. Tissue biopsies from SAT and
VAT, obtained during surgery, were stored at 80C until further processing.
Plasma glucose, insulin, and CRP were determined as described (Todoric
et al., 2011).
Isolation of Preadipocytes
Human SAT was obtained from healthy individuals undergoing lipoaspiration.
A total of 47 donors (female, n = 34; male, n = 13) were used throughout the
study; Total age was 44.02 ± 14.7 years (female, 46.47 ± 14.2; male, 37.62 ±
14.5), and total mean BMI was 25.08 ± 4.3 (female, 24.87 ± 4.5; male,
24.36 ± 3.3). Matched SAT and VAT was obtained from three of the above
donors undergoing elective abdominal surgery. This study was approved by
the Medical University of Vienna’s ethics committee and the General Hospital
of Vienna (EK no. 1115/2010). All subjects gave written informed consent prior
to taking part in the study.
Mouse Studies
Mice were purchased from Charles River Laboratories. Male C57BL/6J,
BKS.Cg-Dock7m+/+ Leprdb/J diabetic (db/db) and nondiabetic (db/+) litter-
mates were used as detailed in the Supplemental Experimental Procedures.
Human and Murine Adipocyte Differentiation
Two-day-postconfluent ASCs were induced to differentiate for 10 to 13 days
with (the medium used is referred to as ‘‘full mix’’ in the text) Dulbecco’s modi-72 Cell Metabolism 18, 62–74, July 2, 2013 ª2013 The Authorsfied Eagle’s medium (DMEM)/Ham’s F12, 10% FBS, 33 mM biotin, 17 mM pan-
tothenic acid, 1 nM triiodothyronine (T3), 870 nM human insulin, 5 mMTZD, and
1 mg/ml transferrin, and for the first 3 days 1 mM Dex and 500 mM isobutyl-
methylxanthine (IBMX) were included (all from Sigma). Two-day-postconfluent
3T3-L1 cells were differentiated with DMEM, 10% CS, 870 nM insulin, 1 mM
Dex, and 500 mM IBMX. On day 3 of differentiation, this medium was added
excluding IBMX and Dex for remaining differentiation. Additional compounds
used were 100 nM HC, 100 nM CC, 1 mM PRD, 5 mM CBTZ, 5 mM FLTZ,
100 mM carbenoxolone, and 1 mM RU486.
Gene Expression Profiling
Was performed as previously described (Bilban et al., 2009). For extended
information on GC target genes and LMO3 targets after GC stimulation, refer
to the Supplemental Experimental Procedures.
Real-Time PCR
Real-time PCR was performed as previously published (Todoric et al., 2011).
Primer sequences are listed in the Supplemental Experimental Procedures.
Adipose Tissue Fractionation
Human ASCs and MA were isolated as described above. ASCs were frac-
tioned by flow cytometry (FACSAria, BD Biosciences) as previously described
(Zeyda et al., 2007).
Luciferase Assays
Luciferase assayswere carried out as previously described (Bilban et al., 2009)
and as detailed in the Supplemental Experimental Procedures.
hASC Transfection
siRNA (100 nmol/liter) (listed in the Supplemental Experimental Procedures) (all
Invitrogen) or plasmids (1 mg) were delivered into hASCs (6 3 105) by Amaxa
nucleofection (Lonza Bioscience) according to manufacturer‘s recommenda-
tions. Cells were utilized 48–72 hr after transfection.
Western Blot Analyses
Western blot analyses were performed as described previously (Bilban et al.,
2009).
Confocal Immunofluorescence Microscopy
All immunofluorescence slides were mounted for imaging with confocal laser
scanning microscopy (LSM 700 Carl Zeiss) as detailed in the Supplemental
Experimental Procedures.
SCID Mouse Xenotransplant Model
All procedures were carried out in accordance with the Association for
Assessment and Accreditation of Laboratory Animal Care guidelines and
the Guide for the Care and Use of Laboratory Animals (US Department of
Health and Human Services, National Institutes of Health, publication no.
86–23). All experiments were approved by the ethics committee of the Med-
ical University of Vienna and by the Austrian government committee on
animal experimentation. For further information, see the Supplemental Exper-
imental Procedures.
Statistical Analysis
The significance of differences between means was assessed by two-tailed
Student’s t test or analysis of variance (ANOVA) with Bonferroni post test. Dif-
ferences between human adipose tissue depots were ascertained by ANOVA.
Correlations were tested by linear regression. Logarithmic transformations
were made if the equal variance and normality assumptions were rejected.
All measurements were adjusted for confounding effects as indicated. Error
bars are expressed as the mean ± SEM unless otherwise specified. p < 0.05
was considered significant.
ACCESSION NUMBERS
Data sets have been deposited in theGene Expression Omnibus (GEO) archive
as series GSE44636.
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